PL2643698T3 - Biomarkery do przewidywania skuteczności immunoterapii raka - Google Patents
Biomarkery do przewidywania skuteczności immunoterapii rakaInfo
- Publication number
- PL2643698T3 PL2643698T3 PL11788121.9T PL11788121T PL2643698T3 PL 2643698 T3 PL2643698 T3 PL 2643698T3 PL 11788121 T PL11788121 T PL 11788121T PL 2643698 T3 PL2643698 T3 PL 2643698T3
- Authority
- PL
- Poland
- Prior art keywords
- biomarkers
- predict
- effectiveness
- cancer immunotherapy
- immunotherapy
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41698110P | 2010-11-24 | 2010-11-24 | |
| GBGB1021289.2A GB201021289D0 (en) | 2010-12-15 | 2010-12-15 | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
| US42365210P | 2010-12-16 | 2010-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2643698T3 true PL2643698T3 (pl) | 2016-12-30 |
Family
ID=43567254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11788121.9T PL2643698T3 (pl) | 2010-11-24 | 2011-11-22 | Biomarkery do przewidywania skuteczności immunoterapii raka |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8669063B2 (pl) |
| EP (1) | EP2643698B1 (pl) |
| JP (1) | JP6005051B2 (pl) |
| KR (1) | KR20130119453A (pl) |
| CN (1) | CN103384827B (pl) |
| AU (1) | AU2011333819A1 (pl) |
| BR (1) | BR112013012820A2 (pl) |
| CA (1) | CA2818738A1 (pl) |
| EA (1) | EA201390762A1 (pl) |
| ES (1) | ES2592957T3 (pl) |
| GB (1) | GB201021289D0 (pl) |
| HU (1) | HUE030005T2 (pl) |
| MX (1) | MX341734B (pl) |
| NZ (1) | NZ609712A (pl) |
| PL (1) | PL2643698T3 (pl) |
| SG (1) | SG190698A1 (pl) |
| WO (1) | WO2012069462A1 (pl) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2536465T3 (es) | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US9026531B2 (en) * | 2012-04-17 | 2015-05-05 | Cerner Innovation, Inc. | Associating multiple data sources into a web-accessible framework |
| KR102103319B1 (ko) | 2012-06-26 | 2020-04-22 | 바이오디식스, 인크. | 면역반응 발생 요법으로 치료하기 위해 암환자들의 선택, 및 선택해제를 위한 질량-스펙트럼법 |
| CN103048453B (zh) * | 2012-12-18 | 2014-11-26 | 苏州浩欧博生物医药有限公司 | 一种糖类抗原ca19-9的纳米磁微粒化学发光测定试剂盒及其制备方法和检测方法 |
| RU2677742C2 (ru) * | 2013-11-07 | 2019-01-21 | Медиал Рисеч Лтд. | Способы и системы оценки риска развития злокачественной опухоли легкого |
| EP2942629A1 (en) * | 2014-05-08 | 2015-11-11 | Universität Würzburg | Predictive markers for successful cancer immunotherapy |
| GB201505585D0 (en) * | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| WO2017008046A1 (en) * | 2015-07-08 | 2017-01-12 | Children's Hospital Medical Center | Loss of transcriptional fidelity leads to immunotherapy resistance in cancers |
| CN112710723B (zh) * | 2015-07-13 | 2024-11-12 | 佰欧迪塞克斯公司 | 受益于pd-1抗体药物的肺癌患者的预测性测试和分类器开发方法 |
| JP7114477B2 (ja) | 2015-12-16 | 2022-08-08 | グリットストーン バイオ インコーポレイテッド | 新生抗原の特定、製造、および使用 |
| WO2017136139A1 (en) | 2016-02-01 | 2017-08-10 | Biodesix, Inc. | Predictive test for melanoma patient benefit from interleukin-2 (il2) therapy |
| CN105624110A (zh) * | 2016-02-29 | 2016-06-01 | 时宏珍 | Hla-a0201限制性抗psa抗原特异性ctl的制备方法 |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| JP7281903B2 (ja) * | 2016-05-09 | 2023-05-26 | アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） | 固形腫瘍を有する患者をクラス分けするための方法 |
| US20190177430A1 (en) * | 2016-08-24 | 2019-06-13 | The Wistar Institute Of Anatomy And Biology | Methods of Treating Cancers With Chemotherapy With Reduced Toxicity |
| CN106198987A (zh) * | 2016-08-31 | 2016-12-07 | 辽宁迈迪生物科技股份有限公司 | 一种用于评价肿瘤免疫细胞疗法的检测标记物及其检测方法和应用 |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| WO2018129301A1 (en) * | 2017-01-05 | 2018-07-12 | Biodesix, Inc. | Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups |
| WO2018156448A1 (en) | 2017-02-21 | 2018-08-30 | The Board Of Regents Of The Uiversity Of Texas System | Prediction and treatment of immunotherapeutic toxicity |
| US10699007B2 (en) * | 2017-03-13 | 2020-06-30 | Oracle International Corporation | Hybrid univariate/multivariate prognostic-surveillance technique |
| KR102018006B1 (ko) * | 2017-06-02 | 2019-09-04 | 이종균 | 대장 직장암 환자와 정상인의 말초혈액 내 면역세포의 분포 차이를 이용하여 면역력을 평가하고 암 발병 유무에 대한 정보를 제공하는 방법 및 이를 이용한 진단키트 |
| CN111465989B (zh) | 2017-10-10 | 2024-06-25 | 磨石生物公司 | 使用热点进行的新抗原鉴别 |
| AU2018373154B2 (en) | 2017-11-22 | 2025-08-07 | Seattle Project Corp. | Reducing junction epitope presentation for neoantigens |
| EP3773691A4 (en) | 2018-03-29 | 2022-06-15 | Biodesix, Inc. | DEVICE AND METHOD FOR IDENTIFICATION OF PRIMARY IMMUNORESISTANCE IN CANCER PATIENTS |
| US20210263045A1 (en) * | 2018-04-06 | 2021-08-26 | The Board Of Regents Of The University Of Texas System | Prediction and treatment of immunotherapeutic toxicity |
| CN108624650B (zh) * | 2018-05-14 | 2022-04-29 | 乐普（北京）医疗器械股份有限公司 | 判断实体瘤是否适合免疫治疗的方法和检测试剂盒 |
| CN110885886B (zh) * | 2018-09-07 | 2023-04-07 | 华中科技大学同济医学院附属协和医院 | 一种胶质母细胞瘤鉴别诊断及胶质瘤生存预后的分型方法 |
| KR102159538B1 (ko) * | 2019-01-11 | 2020-09-24 | 충남대학교 산학협력단 | 폐암 환자의 면역항암제에 대한 치료 반응성 예측용 il-6 마커 및 이의 용도 |
| JP2022523564A (ja) | 2019-03-04 | 2022-04-25 | アイオーカレンツ， インコーポレイテッド | 機械学習を使用するデータ圧縮および通信 |
| EP3948286B1 (en) * | 2019-03-28 | 2025-07-23 | F. Hoffmann-La Roche AG | Cancer prognosis |
| CN111257563B (zh) * | 2020-01-22 | 2022-08-23 | 广州泛恩生物科技有限公司 | Cxcl13检测剂在制备预测免疫治疗效果的试剂盒中的用途 |
| EP4168802A4 (en) * | 2020-06-21 | 2025-03-19 | Oncohost Ltd | HOST SIGNATURES THAT PREDICTE IMMUNOTHERAPY RESPONSE |
| US20230314408A1 (en) * | 2020-07-02 | 2023-10-05 | Gopath Laboratories Llc | Immune profiling and methods of using same to predict responsiveness to an immunotherapy and treat cancer |
| US20230258657A1 (en) * | 2020-07-10 | 2023-08-17 | Sekisui Medical Co., Ltd. | Composition containing tarc, and method for improving storage stability of tarc |
| JP6979149B1 (ja) * | 2020-07-10 | 2021-12-08 | 積水メディカル株式会社 | Ｔａｒｃを含有する組成物、及びｔａｒｃの保存安定性向上方法 |
| CN113219173A (zh) * | 2021-05-11 | 2021-08-06 | 中南大学湘雅医院 | Sh2b1在肺癌诊断中的应用 |
| CN113462776B (zh) * | 2021-06-25 | 2023-03-28 | 复旦大学附属肿瘤医院 | m6A修饰相关联合基因组在预测肾透明细胞癌患者免疫治疗疗效中的应用 |
| CN115058440B (zh) * | 2022-06-08 | 2023-08-15 | 郑州轻工业大学 | 催化合成天然蔗糖酯的工程菌及其构建方法和应用 |
| CN115612737A (zh) * | 2022-08-03 | 2023-01-17 | 皖南医学院第一附属医院（皖南医学院弋矶山医院） | 一种胃癌免疫治疗疗效预测和预后评估的方法及其应用 |
| CN118072954A (zh) * | 2024-02-06 | 2024-05-24 | 江南大学附属医院 | 一种基于trp评分系统的胃癌免疫治疗反应预测方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| JP3490893B2 (ja) * | 1998-06-02 | 2004-01-26 | 富士レビオ株式会社 | 胃癌の診断方法 |
| WO2005098446A2 (en) * | 2004-03-31 | 2005-10-20 | The Johns Hopkins University | Biomarkers for ovarian cancer |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| BRPI0618564A2 (pt) * | 2005-11-02 | 2011-09-06 | Bayer Healthcare Llc | métodos para predição e prognóstico de cáncer e para monitoração de terapia contra cáncer |
| US20090035801A1 (en) * | 2005-12-27 | 2009-02-05 | Power3 Medical Products, Inc. | Twelve (12) protein biomarkers for diagnosis and early detection of breast cancer |
| PL2386860T4 (pl) * | 2006-04-24 | 2015-09-30 | Critical Care Diagnostics Inc | Przewidywanie śmiertelności i wykrywanie poważnej choroby |
| AT504231A1 (de) * | 2006-10-03 | 2008-04-15 | Hans Dr Loibner | Prädiktive parameter |
| NZ582823A (en) * | 2007-07-27 | 2012-04-27 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
| GB0718167D0 (en) * | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| EP2080812A1 (en) * | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
| EP2105740A1 (en) * | 2008-03-28 | 2009-09-30 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Biomarkers for monitoring or predicting the treatment of cancer |
| WO2010003773A1 (en) | 2008-06-16 | 2010-01-14 | Siemens Medical Solutions Diagnostics Gmbh | Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer |
| WO2010076322A1 (en) | 2008-12-30 | 2010-07-08 | Siemens Healthcare Diagnostics Inc. | Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer |
| US20100240546A1 (en) * | 2009-03-20 | 2010-09-23 | Samuel Chun Lap Lo | Use of biomarkers for the diagnosis and prognosis of lung cancer |
-
2010
- 2010-12-15 GB GBGB1021289.2A patent/GB201021289D0/en not_active Ceased
-
2011
- 2011-11-22 EA EA201390762A patent/EA201390762A1/ru unknown
- 2011-11-22 MX MX2013005762A patent/MX341734B/es active IP Right Grant
- 2011-11-22 HU HUE11788121A patent/HUE030005T2/en unknown
- 2011-11-22 CA CA2818738A patent/CA2818738A1/en not_active Abandoned
- 2011-11-22 ES ES11788121.9T patent/ES2592957T3/es active Active
- 2011-11-22 US US13/302,674 patent/US8669063B2/en not_active Expired - Fee Related
- 2011-11-22 KR KR1020137015847A patent/KR20130119453A/ko not_active Ceased
- 2011-11-22 BR BR112013012820A patent/BR112013012820A2/pt active Search and Examination
- 2011-11-22 WO PCT/EP2011/070661 patent/WO2012069462A1/en not_active Ceased
- 2011-11-22 NZ NZ609712A patent/NZ609712A/en not_active IP Right Cessation
- 2011-11-22 AU AU2011333819A patent/AU2011333819A1/en not_active Abandoned
- 2011-11-22 EP EP11788121.9A patent/EP2643698B1/en active Active
- 2011-11-22 PL PL11788121.9T patent/PL2643698T3/pl unknown
- 2011-11-22 CN CN201180056555.2A patent/CN103384827B/zh not_active Expired - Fee Related
- 2011-11-22 SG SG2013035530A patent/SG190698A1/en unknown
- 2011-11-22 JP JP2013540324A patent/JP6005051B2/ja not_active Expired - Fee Related
-
2014
- 2014-01-17 US US14/158,054 patent/US9389235B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130119453A (ko) | 2013-10-31 |
| MX2013005762A (es) | 2013-08-12 |
| JP2014500493A (ja) | 2014-01-09 |
| US20140234347A1 (en) | 2014-08-21 |
| JP6005051B2 (ja) | 2016-10-12 |
| ES2592957T3 (es) | 2016-12-02 |
| EP2643698A1 (en) | 2013-10-02 |
| US20120128702A1 (en) | 2012-05-24 |
| MX341734B (es) | 2016-08-31 |
| AU2011333819A1 (en) | 2013-05-23 |
| EA201390762A1 (ru) | 2013-09-30 |
| CN103384827A (zh) | 2013-11-06 |
| GB201021289D0 (en) | 2011-01-26 |
| CN103384827B (zh) | 2016-06-08 |
| WO2012069462A1 (en) | 2012-05-31 |
| NZ609712A (en) | 2015-05-29 |
| BR112013012820A2 (pt) | 2017-05-09 |
| SG190698A1 (en) | 2013-07-31 |
| EP2643698B1 (en) | 2016-06-22 |
| CA2818738A1 (en) | 2012-05-31 |
| US9389235B2 (en) | 2016-07-12 |
| US8669063B2 (en) | 2014-03-11 |
| HUE030005T2 (en) | 2017-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013012820A2 (pt) | biomarcadores para predizer a eficácia d euma imunoterapia anticâncer | |
| SMT201600135B (it) | Nuovi inibitori della s-nitrosoglutatione riduttasi | |
| SMT201700109B (it) | Inibitori di istone demetilasi | |
| EP2758080A4 (en) | ANTICANCER IMMUNOTHERAPY | |
| EP2625292A4 (en) | KREBSBIOMARKER | |
| EP2536854A4 (en) | PERSONALIZED TUMOR BIOMARKERS | |
| EP2596467A4 (en) | Credit risk mining | |
| FR2966037B3 (fr) | Ensemble balai-eponge | |
| IL252163A0 (en) | Lung cancer biomarkers and uses thereof | |
| PL3296319T3 (pl) | Sposoby leczenia nowotworu jelita grubego | |
| IL221719A (en) | Biomarkers for theranostics | |
| ES2638522T8 (es) | Procedimientos para detectar cáncer | |
| LT3444512T (lt) | Vamzdžių konstrukcija | |
| SMT201600370B (it) | Complessi chelati di oligonucleotidi | |
| IL229319A0 (en) | Biomarkers for lung cancer | |
| LT3284754T (lt) | Antikūnai prieš cd38 | |
| IL220084A (en) | Tumor tissue based biomarkers for bevacizumab combination therapies | |
| BR112013011752A2 (pt) | curtimento não metálico | |
| IL228636A0 (en) | Biomarkers for predicting sensitivity to cancer treatments | |
| EP2775844A4 (en) | BIOMARKER FOR THE RESPONSE TO NAE INHIBITORS | |
| ZA201703026B (en) | Biomarkers for the prediction of incident cancer | |
| EP2638355A4 (en) | TOOL REVOLVER ARRANGEMENT | |
| BR112012019494A2 (pt) | dispositivo elétrico | |
| BR112013000371A2 (pt) | invólucro | |
| EP2558859A4 (en) | MICRO ARRAYS |